Oseltix (Oseltamivir)

Oseltix, an antiviral neuraminidase inhibitor, is indicated for the following influenza‑related conditions.

• Influenza (treatment): shortens the duration of fever, cough and aches, and may reduce the risk of complications such as pneumonia in patients with confirmed or suspected influenza.
• Influenza (post‑exposure prophylaxis): prevents the onset of illness when given to individuals who have been exposed to the virus, reducing the likelihood of developing symptomatic flu.
• Pandemic influenza (treatment): employed under public‑health authority for novel or emerging influenza strains to lessen disease severity and transmission.

• Oseltamivir is a prodrug that is converted in the liver to the active metabolite oseltamivir carboxylate. This metabolite binds to the active site of the influenza virus neuraminidase enzyme, inhibiting its activity. By blocking neuraminidase, the release of newly formed viral particles from infected host cells is prevented, limiting viral spread within the respiratory tract and reducing the severity of infection.

Oseltix may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects

• Nausea
• Vomiting
• Headache
• Diarrhea
• Fatigue

Serious or Rare Side Effects

• Allergic reactions (rash, urticaria, angioedema)
• Neuropsychiatric events (confusion, delirium, abnormal behavior)
• Severe skin reactions (Stevens‑Johnson syndrome, toxic epidermal necrolysis)
• Hepatic injury (elevated transaminases, hepatitis)

Oseltix should be used with appropriate clinical caution.

• Assess renal function: dose adjustment may be required in patients with impaired kidney function.
• Monitor for neuropsychiatric symptoms: especially in children and adolescents during treatment.
• Use with caution in pregnancy: limited data, weigh benefits against potential risks.
• Avoid in patients with known hypersensitivity to oseltamivir or its components.
• Review concomitant medications: potential for drug‑drug interactions may necessitate monitoring.
• Store at room temperature: keep in the original packaging, protect from moisture and heat.

Oseltix may interact with other medicines; some interactions require avoidance while others need monitoring.

Major Interactions (Avoid)

• Concomitant use with probenecid: may increase oseltamivir plasma concentrations and risk of toxicity.
• Administration with live attenuated influenza vaccine: may reduce vaccine efficacy.

Moderate Interactions (Monitor Closely)

• Co‑administration with other neuraminidase inhibitors (e.g., zanamivir): may increase adverse event risk.
• Use with strong CYP3A4 inhibitors (e.g., ritonavir): may alter metabolism of the active metabolite.
• Concurrent NSAID therapy: may exacerbate gastrointestinal side effects.